FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:04:056 | Willingness of patients with psoriatic arthritis to participate in pharmacological and nutritional clinical trials: a cross-sectional study Miriam Perino1|2, Francesca Ingegnoli1|2, Luca Ingrao1|2, Debora Piredu1|2, Antonio Varvaro1|2, Camilla Riboldi1|2, Gilberto Cincinelli2, Francesca Desiati2, Martina Biggioggero2, Orazio De Lucia2, Silvia Casari2, Maria Manara2, Ennio Giulio Favalli1|2, Roberto Caporali1|2 | 1Università degli Studi di Milano, Dipartimento di Scienze Cliniche e di Comunità, Milano; 2ASST G. Pini-CTO, UOC di Clinica Reumatologica, Milano, Italy
155 -
PO:14:195 | Real-world effectiveness of anifrolumab in achieving treatment targets and reducing systemic lupus erythematosus disease burden: 6-month interim analysis of the REVEAL study Chiara Cardelli1|2, Chiara Tani1, Luca Moroni3, Filippo Vesentini4, Francesca Bottazzi5, Micaela Fredi6, Ettore Silvagni7, Matteo Piga8, Flavia Riccio9, Fulvia Ceccarelli10, Ginevra De Marchi11, Edoardo Biancalana12, Gianluca Moroncini13, Rita Mulè14, Mariele Gatto15, Laura Coladonato16, Paola Conigliaro17, Maria Gerosa18, Andrea Picchianti Diamanti19, Benedetta Bianchi20, Federica Maiolini20, Michela Gasparotto20, Serena Guiducci20, Maria Ilenia De Andres20, Alberto Lo Gullo20, Silvia Noviello20, On Behalf Of The Reveal Investigators20, Marta Mosca1. | 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa; 2Department of Medical Biotechnologies, University of Siena, Siena; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milano; 4Rheumatology Unit, Department of Medicine, University of Padua, Padova; 5Department of Internal Medicine and Therapeutics, University of Pavia, Pavia; 6Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia; 7Section of Rheumatology, Department of Medical Sciences, University of Ferrara; AOU Sant'Anna, Ferrara; 8Rheumatology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari; 9Department of Precision Medicine, University of Campania Luigi Vanvitelli, Napoli; 10Rheumatology Unit, Dept. of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Roma; 11Division of Rheumatology, Department of Medicine, Azienda Sanitaria Universitaria del Friuli Centrale, Udine; 12Internal Interdisciplinary Medicine Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze; 13Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona; 14Azienda Ospedaliero-Universitaria di Bologna, Internal Medicine and Rheumatology, IRCCS S. Orsola Malpighi, Bologna; 15Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin; AO Mauriziano, Torino; 16Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari; 17Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University of Rome, Roma; 18Clinical Rheumatology, ASST Gaetano Pini CTO; Department of Clinical Sciences and Community Health, University of Milano, Milano; 19Department of Clinical and Molecular Medicine, Sapienza University of Rome; AOU Sant'Andrea, Roma, Italy; 20Italian REVEAL Study Group Italy, Italy
192 -
PO:38:285 | Cross-sectional analysis: interpretation of nonstatistically significant results in randomised controlled clinical trials in rehabilitation Caterina Mugnai1, Luca Falsiroli Maistrello2|3|4, Giacomo Fiacca3, Michele Perrucchini3, Noemi Corbetta3, Federico Amateis3, Stefano Salvioli3 | 1University of Ferrara; 2ULSS 9 Scaligera, Department of Physical Medicine and Rehabilitation, G. Fracastoro Hospital, San Bonifacio VR; 3Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa; 4School of Physiotherapy, Department of Neuroscience, Biomedicine and Movement, University of Verona, Italy
139 -
PO:31:165 | Prevalence and incidence of skin telangectasia and their association with clinical features: analysis of the European Scleroderma Trials and Research cohort Gemma Lepri1, Lorenzo Tofani2, Silvia Bellando Randone1, Veronica Batani3, Paolo Airò4, Patricia Carreira5, Joerg Henes6, Alexandra Balbir Gurman7, Florenzo Iannone8, Antonella Marcoccia9, Luc Mouthon10, Branimir Anic11, Carolina De Souza Müller12, Armine Haroyan13, Ana Cristina Cordeiro14, Serena Guiducci And Eustar Coll1. | 1University of Florence, Dept of Experimental and Clinical Medicine, AOU Careggi, Division of Rheumatology Florence Italy; 2University of Florence, Dept of Statistics, Informatics, Applications, Florence, Italy; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases UnIRAR, IRCCS San Raffaele, Milano, Italy; 4Scleroderma Unit, UOC Rheumatology and Clinical Immunology, ASST Spedali Civili, Brescia, Italy; 5Dept of Rheumatology, 12 de Octubre University Hospital, Madrid, Spain; 6Centre for Interdisciplinary Rheumatology, Immunology and autoimmune diseases INDIRA, University Hospital Tuebingen, Tuebingen, Germany; 7Rheumatology Institute, Rambam Health Care Campus Haifa Israel; 8Dept of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari, Italy; 9Interdisciplinary Reference Center for Systemic Sclerosis CRIIS Sandro Pertini Hospital, Rome, Italy; 10Dept of Internal Medicine, Cochin Hospital, Paris Cité University, Paris, France; 11Div Clinical Immunology and Rheumatology, Dept Internal Medicine, School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia; 12Rheumatology Division, Hospital de Clínicas da Universidade Federal do Parana, Curitiba, Brazil; 13Dept of Rheumatology, Yerevan State Medical University of Armenia, Yerevan, Armenia; 14Servico Reumatologia Hospital Garcia de Orta Almada, Almada, Portugal.
167 -
PO:16:236 | Achieving a low disease activity state with a corticosteroid dose of 5 mg or less: observational study with anifrolumab in patients with systemic lupus erythematosus in Italy Alessandra Bortoluzzi1, Fulvia Ceccarelli2, Fabio Leo3, Paola Roccatagliata3, Chiara Tani4, Margherita Zen5 | 1Azienda Ospedaliera Universitaria Sant' Anna di Cona, Università di Ferrara Italy; 2Unità di Reumatologia, Università Sapienza Roma Italy; 3AstraZeneca S.p.a. Milano Italy; 4Università di Pisa e Azienda Ospedaliero Universitaria Pisana, Pisa Italy; 5Dipartimento di Medicina DIMED , Divisione di Reumatologia, Università di Padova, Italy
135 -
CO:11:2 | Systemic lupus erythematosus with major neuropsychiatric involvement treated with anifrolumab: literature review and a case report Giulia Rizzo1, Fabio Congiu1, Elisabetta Chessa2, Marta Paola Pireddu1, Elena Ragusa1, Alessandra Oliva1, Marianna Salis1, Alberto Cauli1|2, Matteo Piga1|2 | 1SC Reumatologia, Dipartimento di Scienze Mediche e Salute Pubblica, Università di Cagliari Italy; 2SC Reumatologia, AOU Cagliari Italy
240 -
PO:21:019 | Clinical phenotypes in IgG4-related disease: ACR/EULAR classification and practical limitations Mattia Caliste1, Flavia D'Auria2, Linda Mastromanno1, Francesca Carfora2, Carla Giordano3, Cristiano Alessandri1, Marcella Visentini2, Fabrizio Conti1, Roberta Priori1|4 | 1Dipartimento Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza Università di Roma; 2Dipartimento Medicina Traslazionale e di Precisione, Sapienza Università di Roma; 3Dipartimento Scienze Radiologiche, Oncologiche e Anatomo-patologiche, Sapienza Università di Roma; 4Saint Camillus International University of Health Science, UniCamillus, Roma, Italy
138 -
PO:15:217 | Improved efficacy and safety outcomes in patients with systemic lupus erythematosus treated with belimumab vs. immunosuppressants, in addition to antimalarials and glucocorticoids: a post-hoc summary of five phase 3 trials Mariele Gatto1, Karen H. Costenbader2, Andreas Schwarting3, Julia Hn Harris4, Ciara O'Shea5, Roger A. Levy6, Andrea Doria7 | 1Centro Accademico Reumatologia, Dipartimento Scienze Cliniche Biologiche, Università degli Studi Torino, Osp. Mauriziano, Italy; 2Brigham and Women's Hospital, Divisione di Reumatologia, Infiammazione e Immunità, Harvard Medical School, Boston, MA, USA; 3Università Johannes Gutenberg di Mainz, Centro medico universitario, Germany; 4GSK, Immunologia Biostatistica London, UK; 5GSK, Global Medical Affairs Reumatologia, Dublin, Ireland; 6GSK, Global Medical Affairs Collegeville, PA, USA; 7Divisione di Reumatologia, Dipartimento di Medicina, Università di Padova, Italy
171 -
PO:38:278 | Cognitive behavioural therapy vs. physical therapy for chronic primary low back pain: a systematic review with meta-analysis of randomised controlled trials Luca Castioni1, Stefano Salvioli2 | 1Università degli studi di Ferrara; 2Scuola di fisioterapia Claudiana, Bolzano, Italy
167 -
PO:24:060 | Evaluation of a Large Language Model Performance in Rating Cutaneous Manifestations of Dermatomyositis: A Comparison with Expert Assessors Gianmarco Roselli1, Marco Fornaro1, Swapnasha Panigrahi2, Sara Sabbagh3, Florenzo Iannone1, Vincenzo Venerito1, Latika Gupta4 | 1Università degli Studi di Bari, Unità di Reumatologia, DiMePRe-J Bari, Italy; 2University of Birmingham Birmingham, United Kingdom; 3Medical College of Wisconsin, Unit of Rheumatology, Department of Paediatrics Milwaukee, USA; 4University of Manchester, Manchester Academic Health Centre, Division of muscoloskeletal and deramatological sciences Manchester, United Kingdom
23 -
S13:5 | Association between vasoactive-vasodilating therapy and reduced detection of pulmonary arterial hypertension in systemic sclerosis: evidence from a European Scleroderma Trials and Research study Nicola Farina1, Silvia Bellando-Randone1, Sebastien Sanges2, Hilde Jenssen Bjørkekjær3, Lorenzo Tofani4, Marie-Elise Truchetet5, Vanessa Smith6, Andra Balanescu7, Christina Bergmann8, Yannick Allanore9, Philipp Klemm10, Simona Truglia11, Luca Idolazzi12, Christopher Denton13, Roberta Foti14, Anna Wojteczek15, Emmanuel Chatelus16, Madelon Vonk17, Serena Guiducci1, David Launay2, Eric Hachulla2, Jeska De Vries-Bouwstra18, Anna-Maria Hoffmann-Vold19, Oliver Distler20, Marco Matucci-Cerinic1, Cosimo Bruni1. | 1Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Az, Firenze, Italy; 2Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoi, Lille, France; 3Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway; 4Department of Statistics, Informatics and Applications, University of Florence, Firenze, Italy; 5Rheumatology department, CHU de Bordeaux, Bordeaux, France; 6University of Ghent, Department of Rheumatology, Gent, Belgium; 7Department of Rheumatology, St. Maria Hospital, Carol Davila, University of Medicine and Pharmacy Bucharest Romania; 8Department Internal Medicine 3, University Hospital Erlangen, Erlangen, Germany; 9Rheumatology Department, Université Paris Cité, Cochin Hospital, Paris, France; 10Department of Rheumatology and Clinical Immunology Center, JLU Giessen, Campus Kerckhoff Bad Nauheim Germany; 11Reumatologia, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma, Italy; 12Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy; 13Centre for Rheumatology, Royal Free London and University College London Medical School, London, United Kingdom; 14Division of Rheumatology, A.O.U. Policlinico-San Marco, Catania, Italy; 15Department of Rheumatology, Clinical Immunology, Geriatrics and Internal Medicine, Medical University of Gdansk, Univers Gdansk Poland; 16Department of Rheumatology, University Hospital Strasbourg Strasbourg France; 17Department of rheumatology, Radboud University Nijmegen Medical Center Nijmegen The Netherlands; 18Department of Rheumatology, Leiden University Medical Center Leiden The Netherlands; 19Department of Rheumatology, Oslo University Hospital, Oslo, Norway; 20Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
141 -
PO:02:027 | Fast food, slow damage: ultra-processed foods, Western diet and inflammatory arthritis. A systematic scoping review Gianluca Poncina1, Federica Gardin2, Giacomo Cozzi1, Laura Scagnellato1, Mariagrazia Lorenzin1, Stefano Rizzetto1, Caterina Robusto1, Francesca Oliviero1, Valérie Tikhonoff2, Roberta Ramonda1. | 1Rheumatology Unit, Department of Medicine-DIMED, University - Padova University Hospital, Padova, Italy; 2Department of Medicine-DIMED, University - Padova University Hospital, Padova, Italy.
281 -
PO:31:174 | Increased frequency of anti-RNA polymerase 3 antibodies in patients with systemic sclerosis and silicone breast implants: a multicentre study from the international European Scleroderma Trials and Research cohort Maria Grazia Lazzaroni1, Yolanda Braun-Moscovici2, Elda Piovani1, Claudia Barison1, Liala Moschetti1, Veronica Batani3, Corrado Campochiaro3, Michal Tomcik4, Francesca Motta5, Maria De Santis5, Petros P. Sfikaki6, Masataka Kuwana7, Brigitte Granel8, Roberta Foti9, Virginia Berlingiero10, Joana Caetano11, Yannick Allanore12, Alexandra Balbir-Gurman2, Marco Matucci Cerinic3, Franco Franceschini1, Paolo Airò1. | 1ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy; 2Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion-Israeli Institute of Tecnology, Haifa, Israel; 3Vita-Salute San Raffaele University, San Raffaele Hospital, Milano, Italy; 4Institute of Rheumatology, Praga, Czech Republic; 5IRCCS Humanitas Research Hospital; Humanitas University, Milano, Italy; 6Joint Rheumatology Program, Medical School, National Kapodistrian University of Athens Atene GREECE; 7Nippon Medical School Hospital Tokyo Japan; 8Hôpital Nord de Marseille; Aix-Marseille Université Marsiglia France; 9AOU Policlinico G. Rodolico San Marco, Catania, Italy; 10Azienda Ospedaliera Universitaria Senese, Siena, Italy; 11Fernando Fonseca Hospital, Amadora, Portugal; 12Université Paris Cité, Cochin Hospital, Parigi, France.
158 -
PO:18:264 | Anifrolumab in Systemic Lupus Erythematosus: Bridging Clinical Trial Data with Real-World Evidence Giulia Cassone2, Filippo Santoro1, Caterina Vacchi2, Dilia Giuggioli2, Chiara Cabassi1 | 1UOC Reumatologia, AOU Policlinico di Modena, Università degli studi di Modena e Reggio Emilia Modena e Reggio Emilia, Italy; 2UOC Reumatologia, AOU Policlinico di Modena Modena, Italy
85 -
PO:06:086 | Updated Systematic Literature Review and meta-analysis to Inform the Italian Society of Rheumatology Recommendations on the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease Angelo Fassio1, Marco Sebastiani9|10, Francesco Pollastri1, Chiara Crotti4, Nicola Ughi5, Enrico De Lorenzis6, Silvia Mancuso7, Massimo Radin8, Francesca Cozzini9, Greta Carrara11, Gianpiero Landolfi11, Roberto Rozza11, Andreina Manfredi2|3 | 1Rheumatology Unit, University of Verona, Verona, Italy; 2University of Modena and Reggio Emilia, Reggio Emilia, Italy; 3Rheumatology Unit, AUSL-IRCCS, Reggio Emilia, Italy; 4Bone Disease Unit, Department of Rheumatology and Medical Science, ASST-G.Pini-CTO, Milan, Italy; 5Division of Rheumatology, Multispecialist Medical Department, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy; 6Department of Aging Diseases, Orthopedic and Rheumatology, Rheumatology Division, P. Gemelli, Roma, Italy; 7Rheumatology Unit, Department of Clinical, Internal, Anaesthesiologic and Cardiovascular, Sciences, Sapienza, Roma, Italy; 8CMID, San Giovanni Bosco Hub Hospital ASL Città di Torino and Department of Clinical and Biological Sciences, Turin, Italy; 9Department of Medicine and Surgery, University of Parma, Parma, Italy; 10Rheumatology Unit, AUSL Piacenza, Piacenza, Italy; 11Unità Epidemiologica, SIR, Società Italiana di Reumatologia, Milano, Italy
27 -
PO:18:276 | Use of anifrolumab in the treatment of difficult-to-treat manifestations in systemic lupus erythematosus Antonella Grimaldi1, Giuseppe Alessandrini2, Laura Quarta1, Maria Rita Ricciardi1, Daniela Costanza1, Clara Minerba1, Eugenio Quarta1 | 1UOC Reumatologia Verona; 2Specialista Dermatologo in Libera Professione, Italy
182 -
PO:08:126 | Use of upadacitinib in real-life: the experience of Calabrian rheumatology Vincenzo Raimondo1, Maurizio Caminiti2, Pietro Gigliotti3, Giuseppe Varcasia4, Massimo L'Andolina5, Domenico Olivo6, Roberta Pellegrini7, Pietro Muto8, Marilena Calabria9, Laura Massaro10, Jessica Maria El Luppino11, Salvatore De Bonis12, Giuseppa Pagano Mariano2, Stefania Sorbara3, Virginia Caira4, Mariateresa Cirillo5, Caterina Bruno9, Clodoveo Ferri11 | 1UOC di Reumatologia, Dipartimento SCIAC, Sapienza Università di Roma; 2Dipartimento di Medicina, Clinica di Reumatologia, Università degli Studi di Udine; 3UOC Medicina Interna e Nefrologia, Dipartimento MeSVA, Università degli Studi di L'Aquila; 4UniCamillus, San Camillo Università Internazionale di Scienze della Salute di Roma, Italy; 5Ambulatorio di Reumatologia, Ospedale di Tropea, Tropea, Italy; 6ASP Crotone, Ambulatorio di Reumatologia, Crotone, Italy; 7Ambulatorio di Reumatologia, Ospedale Annunziata di Cosenza, Cosenza, Italy; 8Ambulatorio di Reumatologia, Ospedale di Paola, Paola, Italy; 9Ambulatorio di Reumatologia, SOC di Medicina Interna, AOU Dulbecco, Catanzaro, Italy; 10Ambulatorio di Reumatologia, Ospedale di Praia a Mare, Praia a Mare, Italy; 11Casa di Cura Madonna dello Scoglio, Reparto di Reumatologia, Cotronei, Italy - Affiliazione 12: Ambulatorio di Reumatologia, ospedale di Acri, Acri, Italy
159 -
PO:24:068 | Case Report: ‘Spontaneous Pneumomediastinum in a Patient with MDA5-Positive Dermatomyositis and Severe Pulmonary Fibrosis’ Carlotta Braga1, Margherita Rizzo1, Marta Raschellà1, Beatrice Maranini1, Gioacchino Schifino2, Aldo Carnevale3, Marcello Govoni1, Andrea Lo Monaco1 | 1Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna Ferrara, Italy; 2Respiratory Medicine Unit, Department of Cardio-Thoracic-Vascular Pathologies, Arcispedale Sant'Anna, Ferrara, Italy; 3Radiology Unit, Department of Translational Medicine, University of Ferrara, Italy
38 -
PO:17:252 | The choice between belimumab and anifrolumab: analysis of a monocentric cohort Fabio Congiu1, Elisabetta Chessa2, Giulia Rizzo1, Elena Ragusa1, Marta Paola Pireddu1, Alessandra Oliva1, Marianna Salis1, Mattia Congia2, Maria Maddalena Angioni1, Micaela Rita Naitza1, Alberto Floris2, Alberto Cauli1|2, Matteo Piga1|2 | 1AOU e Università degli studi di Cagliari; 2SC Reumatologia PO Duilio Casula, Cagliari, Italy
175 -
PO:35:234 | Sustained Vasculitis Quiescence and CS Reduction with Mepolizumab 100 mg Francesca Mascia1, Angelo Fassio2, Marco Zurlo1, Davide Chesini3, Francesco Pollastri2, Giovanni Adami2, Davide Gatti4, Maurizio Rossini4, Matteo Maule5, Gianentrico Senna1, Marco Caminati1 | 1University of Verona - Allergology and Clinical Immunology Verona, Italy; 2Policlinico G. B. Rossi - Rheumatology Verona, Italy; 3University of Verona - Faculty of Medicine and Surgery Verona, Italy; 4University of Verona - Rheumatology Verona, Italy; 5Policlinico G. B. Rossi - Allergology and Clinical Immunology Verona, Italy
25 -
PO:03:039 | Extraintestinal manifestations of enteropathic arthritis vary in relation to inflammatory bowel disease behaviour, localization, and extent Bernardo D'Onofrio1, Nicoletta Luciano2|3, Simone Parisi1, Maria Chiara Ditto1, Cristina Bezzio2|4, Enrico Fusaro1, Alessandro Armuzzi2|4, Carlo Selmi2|3 | 1Division of Rheumatology, AOU Città della Salute e della Scienza, Torino, Italy; 2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; 3Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Italy; 4Inflammatory Bowel Disease Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
22 -
PO:26:087 | Rituximab versus glucocorticoids for IgG4-related disease: a European retrospective multi-center study of 167 patients Marco Lanzillotta1, Jens Vikse2, Elisabetta Goni3, Jasmin Mahajne1, Veronica Batani1, Lorenzo Dagna1, Emanuel Della-Torre1 | 1Unit of Immunology, Rheumatology, Allergy, and Rare Disease, IRCCS Ospedale san Raffaele Milano, Italy; 2Department of Rheumatology, Stavanger University Hospital, Stavanger, Norway; 3Department of Medicine II, University Hospital, Ludwig Maximilian University Munich, Munich Germany
64 -
PO:32:176 | Outcomes of upfront combination vs monotherapy with rituximab or mycophenolate mofetil for systemic sclerosis interstitial lung disease: results from a European Scleroderma Trials and Research cohort study Devis Benfaremo1, Corrado Campochiaro2, Gábor Kumánovics3, Christina Bergmann4, Elisabetta Zanatta5, David Launay6, Serena Guiducci7, Mickael Martin8, Carolina De Souza Müller9, Carlomaurizio Montecucco10, Luc Mouthon11, Gabriella Szucs12, Kastriot Kastrati13, Marie-Elise Truchetet14, Madelon Vonk15, Francesco Del Galdo16, Marco Matucci-Cerinic2, Gianluca Moroncini1, Yannick Allanore17. | 1Department of Clinical and Molecular Sciences, Marche Polytechnic University, Marche University Hospital, Ancona, Italy; 2Vita-Salute San Raffaele University, San Raffaele Hospital, Milano, Italy; 3University of Pécs, Department Of Rheumatology And Immunology, Pécs, Hungary; 4University Hospital Erlangen, Department Internal Medicine 3, Erlangen, Germany; 5Padova University Hospital, Rheumatology Unit, Padova, Italy; 6Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Lille, France; 7University of Florence, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy; 8Poitiers University Hospital, Department of Internal Medicine Poitiers France; 9Hospital de Clinicas da Universidade Federal do Parana Curitiba Brazil; 10Università di Pavia e IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy; 11Hôpital Cochin, Department of Internal Medicine, Paris, France; 12University of Debrecen, Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary; 13Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria; 14CHU de Bordeaux, Rheumatology department, Bordeaux, France; 15Radboudumc, Department of Rheumatology Nijmegen The Netherlands; 16Leeds Raynauds and Scleroderma Program, NIHR Biomedical Research Centre, Leeds, United Kingdom; 17Université Paris Cité, Cochin Hospital, Rheumatology Department, Paris, France.
174
1 - 49 of 49 items
